Trial Profile
Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Busulfan (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Dinutuximab (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Filgrastim (Primary) ; Isotretinoin (Primary) ; Levetiracetam (Primary) ; Melphalan (Primary) ; Mesna (Primary) ; Natural killer cell therapy (Primary) ; Sargramostim (Primary) ; Stem cell therapies (Primary) ; Topotecan (Primary) ; Vincristine (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 11 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 01 Aug 2023 According to a Renaissance Pharma media release, company will pursue interaction with the FDA and EMA together with other regulatory agencies around the globe to develop the optimal path to submission.
- 06 Dec 2021 Results (As of November 4, 2020; N= 64) assessing whether combining Dinutuximab throughout therapy improves early response and outcomes in children with newly diagnosed high-risk neuroblastoma, published in the Journal of Clinical Oncology